ACRV · Acrivon Therapeutics, Inc.
AI read · Good for ACRV
The AI's read
The reported patient results give Acrivon early signs that its cancer drug may help some patients. Its new immune-disease programs add another area to develop. The planned review of another cancer trial has not happened yet, and the company expects its cash to last into the fourth quarter of 2027.